药明生物发布Green CRDMO白皮书，驱动生物药行业可持续发展进程

上海,

2025年9月9日

全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）近日在其首届CRDMO⁺ Open Day活动上发布《药明生物Green CRDMO白皮书》，分享端到端生物药绿色解决方案，推动全球生物药行业供应链可持续发展。去年11月，公司的Green CRDMO解决方案成功入选联合国全球契约组织（UNGC）“二十年二十佳企业可持续发展案例”，这是制药行业唯一获此殊荣的案例。

《药明生物Green CRDMO白皮书》系统阐述了公司应对可持续发展及气候变化的战略方针，同时详尽展现药明生物在生物药研究、开发和生产环节的绿色创新技术及公司绿色可持续运营的节能减碳成果。此《白皮书》共汇聚242个优秀节能案例，覆盖生物制药行业12大能源系统及5大关键节能场景，运用25类节能技术。

此外，药明生物积极探寻精益管理与数字化工具与可持续发展的有效融合，旨在提升资源和能源利用效率，持续提升卓越运营水平。2024年，公司超90%已完成的精益改善项目均实现了经济效益和环境效益的双丰收，收获减碳、节水、降废等改善成果。

药明生物深知应对气候变化的重要性，为此制定了应对气候变化的综合战略、科学可量化的目标矩阵以及清晰路线图。近期，药明生物推出更具雄心的碳减排目标矩阵，获得科学碳目标倡议（SBTi）认证，这也将进一步激励公司坚定不移地应对气候变化，并引领行业向净零经济转型。

博士

关于药明生物

Shanghai,

September 9, 2025

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently launched the "WuXi Biologics Green CRDMO White Paper" at its first CRDMO⁺ Open Day event, sharing the end-to-end Green CRDMO solution for biologics and driving the sustainable development of the global biologics industry supply chain. Last November, the company's Green CRDMO solution was also featured in the "20 Case Examples for 20 Years" report initiated by the United Nations Global Compact, making it the only case in the pharmaceutical industry to receive this honor. 

Along with an overall introduction to the company's strategic approach toward sustainability and climate change, the White Paper details WuXi Biologics' green innovation technologies across the research, development and manufacturing of biologics, and showcases the significant carbon reduction achieved through green operations. A total of 242 energy-saving cases are compiled in the White Paper, spanning five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories within the industry.

In addition, the paper highlights how the integration of lean management and digitalization with sustainability enhances resource and energy efficiency, while driving  continuous improvement. In 2024, over 90% of the company's completed Kaizen projects achieved ESG benefits, including reductions in carbon emission, water consumption and waste generation. 

With a deep understanding of the importance of tackling climate change, WuXi Biologics has adopted a comprehensive, integrated strategy with measurable targets and a well-defined roadmap. Recently, the company announced a new target matrix approved by SBTi, an acknowledgement that further inspires its steadfast dedication to leading the way to a net-zero economy.